Skip to main content

Sartorius Stedim Biotech S.A. (DIM.PA)

PAR Healthcare Medical - Instruments & Supplies
44.2Fair

ValueMarkers Composite Index

Top 23%#34,943 of 45,191
Overvalued

586% above intrinsic value ($29)

UndervaluedFair ValueOvervalued
Piotroski
8/9
Strong
Beneish
-2.92
Low Risk
Altman
3.61
Safe
DCF Value
$29
Overvalued
ROIC
5.4%
Low
P/E
62.0
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, filtration, purification, and fluid management services; single-use and reusable hollow-fiber membrane devices, as well as presterilized assemblies for cell and gene therapy applications; and cell harvesting and various other solutions for intensified bioprocesses. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.

CEO: Rene Faber9,961 employeesFRwww.sartorius.com

Deep Dive Analysis

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.